Apple's fiscal Q1 2026 results, fueled by "staggering" demand for the iPhone 17, delivered record revenue and a dramatic turnaround in China, silencing critics and reigniting growth.
Otis Worldwide Corporation (OTIS) is showing signs of a resilient turnaround, with its core service business and booming modernization orders driving growth despite headwinds in new equipment sales, particularly in China. This analysis delves into the investment thesis gaining traction among some fund managers.
Despite a dominant position in analytical instruments, Waters Corporation faces headwinds from a slowing Chinese market and elevated debt. We examine the investment thesis for the life sciences tools provider, weighing its recurring revenue model against current valuation concerns.
Business Facilities magazine has named North Carolina its 'State of the Year' for business climate and economic development, the state's third such win in six years, following a surge of multi-billion dollar investments from tech and manufacturing giants.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
Under new CEO Michael Leiters, Porsche is reportedly considering axing its planned all-electric 718 Boxster and Cayman line. The potential move, driven by development hurdles and soaring costs, signals a strategic recalibration as the automaker grapples with a sales slowdown in China and the financial weight of revising its EV roadmap.
Amidst shifting economic currents in Asia, a class of smaller companies—often overlooked as 'penny stocks'—is attracting attention for their distinct financial profiles and niche market positions. We analyze three such firms with market capitalizations below US$200 million.
Amidst a backdrop of economic recalibration in Japan and cautious optimism in China, select Asian tech firms are leveraging innovation to defy market volatility. We analyze three companies—from gaming to IoT—with the fundamentals to outperform in the year ahead.
Precious metals markets experienced one of their most volatile weeks on record, with silver plummeting 26% and gold dropping 9% in a dramatic reversal. The sell-off, triggered by shifting U.S. policy expectations, laid bare the market's recent dependence on speculative flows from China, raising questions about stability ahead of the Lunar New Year.
Thermo Fisher Scientific posted stronger-than-expected Q4 revenue and profit, driven by new products and strategic deals. However, the stock fell as investors weighed pressures in key academic and government markets against the company's solid 2026 outlook.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
Amidst a complex backdrop of economic crosscurrents and geopolitical tensions, a select group of small-cap companies across Asia are demonstrating remarkable resilience and growth potential. We analyze three standout names from Singapore and China that are navigating the volatility with strong fundamentals.
Chinese EV maker NIO Inc. is hitting new operational highs, reporting record quarterly deliveries and improving margins as its multi-brand strategy gains traction. With a strengthened balance sheet and a global expansion underway, analysts debate whether the company is nearing a crucial inflection point.
Personalis, Inc. (NASDAQ: PSNL) is attracting investor attention with its ultra-sensitive NeXT Personal blood test, capable of detecting cancer recurrence far earlier than standard methods. With a key distribution deal and anticipated Medicare reimbursement, the company could be on the cusp of a significant inflection point.
After years of struggle, Oatly Group AB (OTLY) is showing concrete signs of a sustainable turnaround, posting its first quarterly operating profit in ten years. Strategic moves, including debt restructuring and a key investor stake, are fueling optimism for the oatmilk pioneer's path to profitability.
With its patented, FDA-recognized compound Niagen®, Niagen Bioscience (NAGE) has carved out a unique and defensible position at the intersection of nutraceuticals and pharmaceuticals. As the cellular health market expands, the company's dual-channel strategy and deep scientific validation present a compelling growth narrative for investors.
Stellantis shares have shed over a quarter of their value in the past year, trading at a steep discount to industry peers. A deep dive into valuation metrics suggests the market may be overlooking the carmaker's fundamentals, presenting a potential opportunity for value-focused investors.
Vaxcyte (PCVX) bolsters its financial position with a successful public offering, channeling fresh capital into pivotal late-stage trials for its broad-spectrum pneumococcal vaccine candidate, VAX-31, in both adults and infants.
Pfizer has secured global rights to Novavax's Matrix-M adjuvant technology, aiming to develop new vaccines for infectious diseases as it seeks to diversify its portfolio beyond pandemic-related sales.
A discounted cash flow analysis suggests Hongkong Land Holdings (SGX:H78) is trading close to its intrinsic value. We delve into the model's assumptions and what it means for investors in the current market climate.
